E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 5/1/2006 in the Prospect News Biotech Daily.

ICON reiterated at buy by Jefferies

Jefferies & Co., Inc. analyst David Windley reiterated ICON plc at buy, raising its price target to $60. The company is improving new business and accelerating its central lab trend toward a breakeven mark. ICON reported first-quarter earnings per share of $0.52 on net revenue of $98.5 million, compared with the analyst's estimate $0.52 on $92.7 million. Management raised its forecast for 2006 to $2.35 to $2.45 on $395 million to $410 million of revenue, from $2.20 to $2.30 on $380 million to $400 million of revenue. Shares of the Dublin, Ireland, contract research organization were up $1.14, or 2.09%, at $55.65 on volume of 65,878 shares versus the three-month running average of 32,431 shares. (Nasdaq: ICLR)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.